# NCT03529110 (NCT03529110)

> DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03529110
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Daiichi Sankyo
- Conditions: Breast Cancer
- Interventions: Trastuzumab deruxtecan (T-DXd); Ado-trastuzumab emtansine (T-DM1)
- Enrollment: 524
- Primary outcome: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane

## Commentary we found

- YouTube: 63
- Podcasts: 63
- X threads: 22
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct03529110

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03529110", "email": "<work email>"}; the inbox owner confirms by the emailed link.